PT83933B - Processo para a preparacao de composicoes estaveis de activador do plasminogenio humano, tipo tecido - Google Patents

Processo para a preparacao de composicoes estaveis de activador do plasminogenio humano, tipo tecido

Info

Publication number
PT83933B
PT83933B PT83933A PT8393386A PT83933B PT 83933 B PT83933 B PT 83933B PT 83933 A PT83933 A PT 83933A PT 8393386 A PT8393386 A PT 8393386A PT 83933 B PT83933 B PT 83933B
Authority
PT
Portugal
Prior art keywords
plasminogen activator
preparation
tissue type
human plasminogen
stable compositions
Prior art date
Application number
PT83933A
Other languages
English (en)
Other versions
PT83933A (en
Inventor
Stuart E Builder
William Franklin Bennett
Larry Alan Gatlin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT83933(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT83933A publication Critical patent/PT83933A/pt
Publication of PT83933B publication Critical patent/PT83933B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT83933A 1985-12-17 1986-12-15 Processo para a preparacao de composicoes estaveis de activador do plasminogenio humano, tipo tecido PT83933B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions

Publications (2)

Publication Number Publication Date
PT83933A PT83933A (en) 1987-01-01
PT83933B true PT83933B (pt) 1989-01-17

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
PT83933A PT83933B (pt) 1985-12-17 1986-12-15 Processo para a preparacao de composicoes estaveis de activador do plasminogenio humano, tipo tecido

Country Status (23)

Country Link
US (2) US4777043A (pt)
EP (1) EP0228862B1 (pt)
JP (2) JPH0714886B2 (pt)
KR (1) KR950010322B1 (pt)
AT (1) ATE79273T1 (pt)
AU (1) AU600246B2 (pt)
DD (1) DD255477A5 (pt)
DE (2) DE3642960A1 (pt)
DK (1) DK174203B1 (pt)
ES (1) ES2044840T3 (pt)
FI (1) FI88873C (pt)
FR (1) FR2591485B1 (pt)
GB (1) GB2184354B (pt)
GR (1) GR3006078T3 (pt)
HU (1) HU200101B (pt)
IE (1) IE59060B1 (pt)
IL (1) IL80904A (pt)
MY (1) MY102185A (pt)
NO (1) NO168988C (pt)
NZ (1) NZ218612A (pt)
PH (1) PH24716A (pt)
PT (1) PT83933B (pt)
ZA (1) ZA869457B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
ATE264340T1 (de) * 1999-08-17 2004-04-15 Novo Nordisk Healthcare Ag Stabilisierung von gefriergetrocknetem kuchen
ES2200973T3 (es) * 1999-11-04 2004-03-16 Genentech, Inc. Ensayo.
MXPA02009485A (es) 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
KR20040062535A (ko) * 2001-09-07 2004-07-07 글로벌 바이오텍 인코포레이티드 인간 조직 유로키나아제형 플라스미노겐 활성화제 배합물
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
JP6649246B2 (ja) * 2013-03-14 2020-02-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3273732D1 (en) * 1982-12-30 1986-11-20 Kowa Co Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
ATE68825T1 (de) * 1985-04-22 1991-11-15 Genentech Inc Plasminogenaktivator-mutante des menschlichen gewebes, verfahren und zwischenprodukte dafuer und diese mutante verwendende zusammensetzungen.
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ES8706443A1 (es) * 1985-05-28 1987-07-01 Wellcome Found Un procedimiento para preparar una solucion parenteral de activador de plasminogeno de tejido (t-pa)
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
MY102185A (en) 1992-04-30
ATE79273T1 (de) 1992-08-15
JPH0714886B2 (ja) 1995-02-22
DE3642960A1 (de) 1987-06-19
IL80904A0 (en) 1987-03-31
FR2591485B1 (fr) 1989-07-28
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
GB2184354B (en) 1990-04-11
AU6661086A (en) 1987-06-18
PH24716A (en) 1990-10-01
FI865159A (fi) 1987-06-18
KR950010322B1 (ko) 1995-09-14
EP0228862A3 (en) 1988-09-28
FR2591485A1 (fr) 1987-06-19
NZ218612A (en) 1989-07-27
PT83933A (en) 1987-01-01
ES2044840T3 (es) 1994-01-16
US4777043A (en) 1988-10-11
IL80904A (en) 1992-01-15
FI865159A0 (fi) 1986-12-17
NO865079D0 (no) 1986-12-16
GB2184354A (en) 1987-06-24
US4908205A (en) 1990-03-13
AU600246B2 (en) 1990-08-09
DK605786A (da) 1987-06-18
GB8629981D0 (en) 1987-01-28
NO168988B (no) 1992-01-20
JPH07173076A (ja) 1995-07-11
FI88873C (fi) 1993-07-26
JPS62164632A (ja) 1987-07-21
DE3686410T2 (de) 1993-02-18
ZA869457B (en) 1988-08-31
IE59060B1 (en) 1993-12-15
EP0228862A2 (en) 1987-07-15
DE3686410D1 (de) 1992-09-17
KR870005647A (ko) 1987-07-06
DK605786D0 (da) 1986-12-16
DK174203B1 (da) 2002-09-16
NO168988C (no) 1992-04-29
EP0228862B1 (en) 1992-08-12
GR3006078T3 (pt) 1993-06-21
NO865079L (no) 1987-06-18
DD255477A5 (de) 1988-04-06
HU200101B (en) 1990-04-28
FI88873B (fi) 1993-04-15

Similar Documents

Publication Publication Date Title
PT83933B (pt) Processo para a preparacao de composicoes estaveis de activador do plasminogenio humano, tipo tecido
NO830110L (no) 6-substituert-s-triazolo(3,4-a)ftalazinderivater og fremgangsmaate for deres fremstilling
GR900100326A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
IT8123940A0 (it) Derivati della s-adenosilmetionina, processo per la loro preparazione e composizioni terapeutiche che licontengono come principio attivo.
ES288272Y (es) Cuerpo fragmentador para granadas,particularmente granadas de mano
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas
PT83253A (en) Process for preparing p-acylaminobenzamides
SE8500822D0 (sv) Diazepinoindoles, their production and pharmaceutical compositions containing them
SE8503513L (sv) Farmaceutiska och kosmetiska kompositioner, vilka som verksam bestandsdel innehaller acetyl-10-triacetoxi-1,8,9-antracen
DK239084D0 (da) 2-alkylthio-1-aminoalkyl-2-pyrrolin-3-carbonitriler
DK98788D0 (da) Benzylaminoaryl-dihydropyridinlactoner, fremgangmsaade til deres fremstilling samt deres anvendelse som laegemidler